MediciNova Completes Patient Enrollment In Its Phase 2 MN-001-NATG-202 Trial Of MN-001 (Tipelukast) For Hypertriglyceridemia And Non-alcoholic Fatty Liver Disease Due To Type 2 Diabetes, Top-Line Data Are Expected By The Summer Of 2026
Benzinga Newsdesk 12 months ago
BiotechNewsHealth CareGeneral
The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001(tipelukast). Patients are randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo
The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001(tipelukast). Patients are randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks. The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2) change from baseline in fasting serum triglycerides at Week 24. Secondary endpoints include safe24 and tolerability and changes in lipid profile (HDL-C, LDL-C, and total cholesterol). Top-line data are expected by the summer of 2026